Literature DB >> 7975207

Activity and cleavage site specificity of an anti-HIV-1 hairpin ribozyme in human T cells.

O Yamada1, G Kraus, M C Leavitt, M Yu, F Wong-Staal.   

Abstract

Human CD4+ T cells (Molt-4) were transduced with retroviral vectors containing a hairpin ribozyme which targets the rev/env coding region of HIV-1 RNA (HXB2: 8629-8644). This target sequence is conserved among many HIV-1 clones, including the prototype virus HXB2, but the infectious clone SF2 contains a single nucleotide substitution at the cleavage site (from N*GUC to N*UUC). Cells stably expressing the ribozyme or its disabled counterpart were challenged with HXB2 or SF2 and the amount of p24 antigen produced was monitored. While this ribozyme was effective in inhibiting the replication of HXB2 in Molt 4 cells, it showed only marginal inhibitory effect on SF2 replication. The same level of virus production was observed with cells transduced by the disabled ribozyme, which functions essentially as an antisense molecule. Expression of the ribozyme was comparable in HXB2- or SF2-infected cells as detected by reverse transcription-polymerase chain reaction. These data provide in vivo evidence that the antiviral activity of the hairpin ribozyme is strictly dependent on the presence of the cleavage site in the target RNA and supports the conclusion that the ribozyme acts as catalytic RNA rather than as antisense RNA in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7975207     DOI: 10.1006/viro.1994.1626

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  12 in total

1.  Cross-clade inhibition of HIV-1 replication and cytopathology by using RNase P-associated external guide sequences.

Authors:  Gunter Kraus; Rebeca Geffin; Gina Spruill; Andrea K Young; Rachel Seivright; Diana Cardona; Jennifer Burzawa; H James Hnatyszyn
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

2.  Hammerhead ribozymes selectively suppress mutant type I collagen mRNA in osteogenesis imperfecta fibroblasts.

Authors:  P A Dawson; J C Marini
Journal:  Nucleic Acids Res       Date:  2000-10-15       Impact factor: 16.971

3.  Factors governing the activity in vivo of ribozymes transcribed by RNA polymerase III.

Authors:  S Koseki; T Tanabe; K Tani; S Asano; T Shioda; Y Nagai; T Shimada; J Ohkawa; K Taira
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

4.  Inhibition of human immunodeficiency virus replication by the herpes simplex virus virion host shutoff protein.

Authors:  T Hamouda; R McPhee; S C Hsia; G S Read; T C Holland; S R King
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

Review 5.  Development of HIV vectors for anti-HIV gene therapy.

Authors:  E Poeschla; P Corbeau; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

6.  A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1.

Authors:  O Yamada; G Kraus; L Luznik; M Yu; F Wong-Staal
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

7.  Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades.

Authors:  A Gervaix; X Li; G Kraus; F Wong-Staal
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

8.  Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.

Authors:  L Q Sun; L Wang; W L Gerlach; G Symonds
Journal:  Nucleic Acids Res       Date:  1995-08-11       Impact factor: 16.971

9.  A new antisense tRNA construct for the genetic treatment of human immunodeficiency virus type 1 infection.

Authors:  M A Biasolo; A Radaelli; L Del Pup; E Franchin; C De Giuli-Morghen; G Palu
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  Cleavage by RNase P of gene N mRNA reduces bacteriophage lambda burst size.

Authors:  Y Li; S Altman
Journal:  Nucleic Acids Res       Date:  1996-03-01       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.